RE: Decent RNS18 Oct 2022 12:29
I'll be honest, I was getting cold feet about the company before yesterday...was expecting a really dire update and had lost faith a bit. But the 33% growth ex Morbid and the cash buildup, professionalism of the update in the afternoon, and taking into account current valuation levels, the high levels of director buying...lots of great positives. Right now you are paying 20x earnings for a company growing 50% yoy, while it's substantially net cash.